MedPath

Cristal Delivery B.V.

🇳🇱Netherlands
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

7

Active:3
Completed:3

Trial Phases

2 Phases

Phase 1:4
Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials

Phase 1
4 (66.7%)
Phase 2
2 (33.3%)

Efficacy Study of CPC634 (CriPec® Docetaxel) in Platinum Resistant Ovarian Cancer

Phase 2
Completed
Conditions
Ovarian Cancer
Cancer
Interventions
Drug: CPC634 (CriPec® docetaxel)
First Posted Date
2018-11-15
Last Posted Date
2020-12-28
Lead Sponsor
Cristal Therapeutics
Target Recruit Count
25
Registration Number
NCT03742713
Locations
🇧🇪

Universitaire Ziekenhuizen Leuven, Leuven, Belgium

🇧🇪

CHU de Liège, Liège, Belgium

🇳🇱

University Medical Center Groningen, Groningen, Netherlands

and more 5 locations

A Study of CriPec® Docetaxel Given to Patients With Solid Tumours

Phase 1
Completed
Conditions
Cancer
Metastatic Cancer
Solid Tumors
Interventions
First Posted Date
2015-05-13
Last Posted Date
2018-09-24
Lead Sponsor
Cristal Therapeutics
Target Recruit Count
33
Registration Number
NCT02442531
Locations
🇧🇪

University Hospital Leuven, Leuven, Belgium

🇳🇱

VUMC Amsterdam, Amsterdam, Netherlands

🇳🇱

UMC Groningen, Groningen, Netherlands

and more 1 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.